United States

Innate Pharma SA (IPH.PA)

IPH.PA on Paris Stock Exchange

11:37am EST
Change (% chg)

€-0.56 (-4.00%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for IPH.PA


Innate Pharma SA is a France-based biopharmaceutical Company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of... (more)


Beta: 1.25
Market Cap(Mil.): €754.83
Shares Outstanding(Mil.): 53.92
Dividend: --
Yield (%): --


  IPH.PA Industry Sector
P/E (TTM): -- 42.12 30.77
EPS (TTM): -0.05 -- --
ROI: -1.29 -0.81 15.23
ROE: -4.20 -1.52 16.56

French cancer specialist Innate Pharma can remain independent, for now: CEO

PARIS France's Innate Pharma believes that its cash position and portfolio are sufficiently robust for the cancer drug company to remain independent for the time being and will seek co-development deals modeled on an agreement struck with AstraZeneca in April.

Nov 25 2016

BRIEF-Innate Pharma interim phase 1/2 data for lirilumab in combination with opdivo (nivolumab)

* Reported on Saturday interim phase 1/2 data show encouraging clinical benefit for lirilumab in combination with opdivo (nivolumab)

Nov 14 2016

BRIEF-Innate Pharma preliminary phase 1/2 efficacy data

* Preliminary phase 1/2 efficacy data of lirilumab in combination with opdivo (nivolumab)

Nov 08 2016

BRIEF-Innate pharma Q3 revenue up to 11.2 million euros

* Q3 cash, cash equivalents and financial assets amounting to 239.6 million euros ($266.29 million)

Nov 03 2016

BRIEF-Innate Pharma encouraging initial results for IPH4102

* Preliminary data from dose-escalation part of an ongoing Phase I trial in elderly and heavily pretreated patients including a majority of patients with sezary syndrome

Oct 26 2016

BRIEF-Innate Pharma to present results for IPH4102 at the 3WCCL

* Preliminary safety and clinical activity results for IPH4102 to be presented at the 3WCCL Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Oct 13 2016

BRIEF-Innate Pharma announced data for two Phase I studies for lirilumab and nivolumab

* Announced on Sunday safety data for two Phase I studies conducted by Bristol-Myers Squibb

Oct 10 2016

BRIEF-Innate Pharma H1 net loss narrows to 3.2 million euros

* H1 revenue and other income amounting to 20.7 million euros ($23.28 million)(4.6 million euros for first half of 2015)

Sep 08 2016

Earnings vs. Estimates